Elixir Medical (Milpitas, Calif., and Tokyo) announced that its DynamX® Sirolimus-Eluting Coronary Bioadaptor System for the treatment of cor...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has entered into a drug ...
Eisai Co., Ltd. and Biogen Inc., announced that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of...
Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced two major clinical mi...
Eisai Co., Ltd. and Biogen Inc., announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in th...
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Au...
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML Innovent Biologics, Inc. (01801.HK) and ...
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical T...
CellFiber Co., Ltd. (“CellFiber”), a Tokyo-based biotechnology company built on its proprietary CellFiber® cell encapsulation platform, a...
Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...
Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...
Ember LifeSciences, Inc. ("Ember"), an award-winning provider of advanced pharmaceutical cold chain solutions, has entered into a capital and business al...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
© 2026 Biopharma Boardroom. All Rights Reserved.
